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Abstract This article highlights the features that connect
priondiseases withother cerebral amyloidoses and how these
relate to neurodegeneration, with focus on tau phosphoryla-
tion. It also discusses similarities between prion disease and
Alzheimer’s disease: mechanisms of amyloid formation,
neurotoxicity, pathways involved in triggering tau phosphor-
ylation, links to cell cycle pathways and neuronal apoptosis.
We review previous evidence of prion diseases triggering
hyperphosphorylation of tau, and complement these ﬁndings
with cases from our collection of genetic, sporadic and
transmitted forms of prion diseases. This includes the novel
ﬁnding that tau phosphorylation consistently occurs in spo-
radic CJD, in the absence of amyloid plaques.
Cerebral amyloid, tau phosphorylation and cell death:
how are they connected?
Human prion diseases represent a clinically and patholog-
ically diverse group of neurodegenerative disorders
including (1) sporadic Creutzfeldt–Jakob disease (sCJD),
(2) inherited forms of prion diseases (inherited prion dis-
ease, IPD) such as Gerstmann–Stra ¨ussler–Scheinker
syndrome (GSS) or fatal familial insomnia (FFI) and (3)
acquired forms, such as variant CJD (vCJD), iatrogenic
CJD (iCJD) and Kuru. We avoid the term ‘‘familial CJD’’,
as CJD was originally deﬁned as a clinicopathological
syndrome which is distinct from e.g. GSS or FFI. The term
IPD links the different syndromes by pathogenesis and is
therefore preferred.
According to the protein-only hypothesis [40], infectious
prions are composed predominantly, if not entirely, of
aggregates of misfolded, host-encoded, cellular prion protein
(PrP
C), commonly designated PrP
Sc [83]. PrP
Sc arises from
normal prion protein (PrP
C) through conformational conver-
sion.Thecommonneuropathologicalfeatureofpriondiseases
is a predominantly extracellular accumulation of PrP
Sc in the
central nervous system. Prion protein deposits are highly
variable in their intensity (Fig. 1;T a b l e1), pattern, i.e. pla-
ques(Fig. 1m–o),perineuronallabelling(Fig. 1p–r),synaptic
deposition (Fig. 1j–l) and formation of coarse granular
deposits (Fig. 1g–i) and their distribution within the CNS.
These deposits correspond biochemically to amyloid, i.e.
aggregates of protein with high content of b-sheets. The
deposits are accompanied by spongiform change with neu-
ronal vacuolation and degeneration(Fig. 1a–f)and astrocytic
and microglial reaction, all of which can vary considerably
within the CNS and between different individuals.
Whilst prion diseases can be readily transmitted via
various routes and between species, the most common Ab
amyloidosis is transmissible at a considerably lower efﬁ-
ciency, and has to date been limited to experimental
settings [29]. Another well recognised CNS amyloidosis,
familial British dementia (FBD) has not been experimen-
tally tested for transmissibility.
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DOI 10.1007/s00401-010-0691-0In the last few years, a striking number of epidemio-
logical, neuropathological, and biochemical similarities
between prion diseases and Alzheimer’s disease have been
identiﬁed, in particular the fact that there are interactions
between the two proteins [41, 59, 74] and between the
signalling pathways involving both proteins.
Epidemiologically and clinically, both disorders are
dementing illnesses that mainly occur sporadically, but can
also occur as familial forms. Histopathologically, both are
characterised by the deposition of an extracellular amyloid
that is produced by neurones. In both diseases, there is
formation of amyloid oligomers and ultimately also of
solid amyloid aggregates in the brain (Figs. 1g–o, 2a–f;
Table 1): both amyloid proteins can accumulate diffusely
(Fig. 2a–c), or they can exhibit prominent and widespread
deposition of dense amyloid plaques with a diameter of
more than 200 lm (Fig. 2d–f), and both elicit a consider-
able astrocyte and microglial reaction, variable neuronal
Fig. 1 Spongiform changes and
PrP deposition in sporadic prion
disease: severity of spongiform
changes, ranging from mild to
moderate and severe, with
diffuse, homogenous
spongiform changes (a–c) and
patchy conﬂuent vacuolisation
(d–f). Patterns and intensities of
commonly observed prion
protein deposits: g–i coarse
granular deposits of prion
protein, which may form
conﬂuent aggregates. j–l
Synaptic PrP, ranging from mild
to severe, and m–o, formation
of plaques in sporadic CJD. All
patterns and intensities are used
in the scoring scheme to
compare with tau burden in our
series; 160 lm( a–c, m–o),
300 lm( d–f, p–r), 80 lm( j–l)
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123loss, and occasionally deposition of amyloid in or around
vessels walls.
Biochemically, both diseases are characterised by
aggregation of a protein that is encoded and expressed by
the host. It was recently suggested that Ab42 may act
through a PrP receptor [41, 59]. Experimental data suggest
that there is a functional link between PrP
C and Ab pro-
cessing: (1) knockdown of PrP
C in N2A cells increases Ab
levels in vitro, (2) PrP knockout mice as well as scrapie-
infected mice show increased Ab level and (3) PrP
C
overexpression reduces Ab formation by downregulating
the APP cleaving enzyme b-secretase [77].
Recent genetic evidence also links prion disease to
Alzheimer’s disease, in that the APOE-E4 allele, a well-
established risk factor for AD, also may increase the risk
for sporadic CJD [57], but surprisingly may delay onset of
inherited prion disease with the P102L mutation [92]. A
detailed discussion of the similarities between CJD and
AD, the relationship between codon 129 polymorphism
and a model of Ab42 action through PrP
C receptor are
given in a review by Gunther and Strittmatter [41].
The amyloid cascade hypothesis
According to the amyloid cascade hypothesis, proposed by
Hardy and Higgins [44] the increased production or
decreasedclearance of amyloid beta (Ab) peptides results in
the accumulation of the hydrophobic Ab40 and Ab42 pep-
tideswithsubsequentaggregationandformationofinsoluble
plaques. This inducesacascadeof deleteriouschanges,such
as neuronal death and eventually causes Alzheimer’s
disease. Since then, this hypothesis underwent several
transformations due to the accumulating data supportive of
or inconsistent with the theory [81]. The current version
assumes a toxic role of soluble preﬁbrillar oligomers based
on the several in vivo and in vitro experiments [37, 42]. The
results contradicting these ﬁndings [61, 86, 90] and the
recognised experimental artifacts [7] make it more difﬁcult
to elucidate their genuine role in disease development.
However,anumberofrecentstudiesintransgenicmicehave
further strengthened the concept of the amyloid cascade
hypothesis: intracerebral injection of Ab seeds trigger the
aggregation of endogenous Ab: intracerebral inoculation of
APP23 transgenic mice with brain homogenates from Alz-
heimer’s patients or with brain extracts from aged APP23
transgenicmiceelicitsamarkedanticipationofthediseasein
young APP23 mice [69]. This ﬁnding can be interpreted as
prion-like transmission or as seeding process. The latter is a
more likely scenario, as implantation of small steel wires
coated with minute amounts of Ab-containing brain
homogenate into the brain of APP23 transgenic mice trig-
gered signiﬁcant deposition of Ab in the CNS, whilst
peripheral inoculation of these mice with Ab did not seed in
the CNS [29]. It may be argued that the presence of a prion
receptor, but not of an ‘‘Ab’’ receptor in peripheral tissues,
such as nerve endings or immune cells.
Cerebral amyloid and tau hyperphosphorylation:
what is the trigger?
A prominent feature of cerebral amyloidoses is the induc-
tion of tau hyperphosphorylation. This is very well
Fig. 2 Intensities of Ab deposits: a–c diffuse protein deposits
without formation of plaques (ranging from mild to severe). a Score
1 (mild) describes occasional patchy deposits, occasionally seen on
low power magniﬁcation. b Moderate, score 2 describes deposits that
are seen in \50% of adjacent low power ﬁelds. c An example of
heavier diffuse amyloid beta burden, indicating a presence in most of
the low power ﬁeld on a cortex section. Dense core amyloid beta
plaques, approximately corresponding to CERAD sparse (d), inter-
mediate (e) and high (f). Scale bar 300 lm( a–f, g–i)
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123established for Alzheimer’s disease (AD), but is also a
prominent feature in the rare FBD and has been sporadi-
cally described for prion diseases mostly in the context of
the presence of plaques, such as in vCJD or in many
inherited forms. A prominent feature of AD is the accu-
mulation of hyperphosphorylated tau within or in the
vicinity of cortical amyloid deposits (Fig. 3d–f). Impor-
tantly, this direct association of tau pathology in areas of
Ab accumulation has to be separated from a probably
independent process of tau phosphorylation that starts in
the entorhinal cortex and spreads over the limbic system
and ﬁnally extends into neocortical regions. This latter
process has been characterised in detail and was formalised
in a staging system developed and deﬁned by Braak and
Braak [10, 11]. The clinical dementia correlates better with
the Braak stage than with the deposition of Ab.
FBD is an autosomal dominant, neurodegenerative dis-
order, presenting with dementia, spastic tetraparesis, and
cerebellar ataxia, also known as Worster–Drought syn-
drome [68, 82, 85, 94]. Similar to Alzheimer’s disease,
in particular its inherited forms, the neuropathological
hallmarks of FBD include extensive cerebral amyloid
angiopathy (CAA), cerebellar degeneration with severe
CAA and parenchymal amyloid plaques. There are also
hippocampal amyloid plaques as well as neuroﬁbrillary
tangles, and white matter degeneration similar to that seen
in Binswanger’s disease [50]. Deposition of hyperphos-
phorylated tau in FBD is indistinguishable from that in AD,
both immunohistochemically and ultrastructurally.
In prion disease, hyperphosphorylation of tau has been
described, but it is not a well-known or well-characterised
feature. Not much is known about the relationship between
disease duration, PRNP codon 129 genotype, glycotype,
histological manifestations and the degree of tau phos-
phorylation. Several studies have reported the deposition
of hyperphosphorylated tau in small series of sporadic,
familial and variant forms of prion diseases. These reports
highlight the role of prion amyloid plaques as an essential
prerequisite to elicit tau phosphorylation and raise impor-
tant questions related to the mechanism responsible for tau
phosphorylation. A detailed discussion of these reports is
given below.
Ab, PrP and tau: their connection to cell cycle
and cell death
Several pathways are thought to play a role in neurode-
generative processes, some of which are unusual suspects.
A number of cell cycle proteins have recently been
implicated in neurodegenerative processes. CDK5, GSK3b,
and pAkt are all well-characterised mediators of growth,
survival and inhibitors of neur(on)al differentiation. All are
now also linked to the family of neurodegeneration—prion
protein, Ab and tau phosphorylation.
CDK5, a serine-threonine kinase, is a cell cycle protein
that is also responsible for processes, such as axonal
guidance, cortical layering and synaptic structure/plastic-
ity, and it is mainly expressed in postmitotic neurones [18,
78]. Dysregulation of CDK5 has been implicated in neu-
rodegeneration for some years [17, 18, 20, 71, 78, 88] and
it is now likely to be involved in abnormal phosphorylation
Fig. 3 Amyloid beta or PrP induced pattern of tau phosphorylation
differ: a–c the range of PrP induced tau deposits. The scores of tau
correspond to the scores of PrP shown in Fig. 1, i.e. tau score 1 is
typically seen in areas with PrP score 1 and dense tau deposits (scores
2 or 3) is typically seen in areas with PrP scores 2–3. d–f In contrast,
Ab induces a threaded tau phosphorylation pattern, with elongated
dystrophic neuritis but very little stub- or rod-tau. All examples are
from the frontal or parietal cortex, and correspond to diffuse a beta
deposits scores 1–3. Scale bar 25 lm( a–f)
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123of tau. In keeping, CDK5 inhibition alleviates tau phos-
phorylation and cytoskeletal lesions [96].
GSK3b has recently been identiﬁed as a likely candidate
directly to phosphorylate tau and mechanistic links
between GSK3b, tau [60, 84] and Ab [45, 46, 51] have
been established. A less well described, but mechanisti-
cally appealing connection has also been made to PrP,
which makes the hypothesis of cell cycle related proteins
and neurodegeneration attractive [79].
Another pathway that has been implicated in neurode-
generation involves PTEN/pAkt. The tumour suppressor
PTEN antagonises the phosphorylation of Akt, hence
downregulation of PTEN increases the phosphorylated,
active form of Akt (pAkt), which has pro-survival, pro-
proliferation effects and counteracts apoptosis and cell
differentiation. However, whilst this function of pAkt is
important and relevant for cells capable of self-renewal and
proliferation, i.e. the developing CNS, it is different for
quiescent/postmitotic cells, such as neurons, where con-
stitutive activation of Akt can cause neurodegeneration
[67], including abnormal phosphorylation of tau, mediated
by CDK5 in a GSK3b independent fashion [56, 71]. Whilst
the role of Ab triggering tau phosphorylation is well
established [9, 38, 62, 75], a recent study also showed that
tau phosphorylation is transmissible too, which may have
wide ranging implications for the concept of the involve-
ment of Ab as the sole trigger for hyperphosphorylated tau
in Alzheimer’s disease [23].
Experimental evidence for the connection of tau, Ab and
PrP comes from work of from Perez et al. [79]. Using PrP
106–126 peptides, a widely used paradigm to test prion
toxicity in vitro, GSK3b mediated tau phosphorylation was
induced. Other studies provide compelling evidence that
CDK5, PrP and Ab are mechanistically connected and
involved in neurodegeneration [64, 65].
The PrP–tau connection (I): inherited prion diseases
and phosphorylation of tau
Inherited prion diseases display a wide spectrum of path-
ological deposition of prion protein. The formation of
conspicuous and well-demarcated amyloid plaques is typ-
ically seen in inherited forms with codon P102L (Figs. 4m,
5c) P105L, and A117V mutations (Figs. 4n, 5d), whilst
D178N or E200K (Figs. 4o, 5e) mutations show less
well-deﬁned plaque pathology. Other mutations, such as
octapeptide repeat insert (OPRI) mutations present histo-
logically with a unique striping pattern of the cerebellum
(Fig. 4k, l).
Reports of tau pathology in inherited prion diseases
consistently describe marked dystrophic neurites with
hyperphosphorylated tau, accentuated in the vicinity or
located within amyloid plaques. The ﬁrst reports were those
of classical GSS with the PRNP P102L mutation [5, 8, 34,
35, 73, 89]. Later studies of P102L GSS with detection of
abundant phospho-tau concluded that this may be an effect
of PrP-mediated phosphorylation rather than a Ab related
effect, as there were only minimal Ab deposits seen [52].
However, it may be argued that this latter study detected tau
phosphorylation in the entorhinal cortex which has formed
independently from the prion amyloid deposition, in the
context of Alzheimer’s disease corresponding to Braak and
Braak stage I. Other mutations associated with the clinical
phenotype of GSS (A117V mutation [91]), or P105L [53,
95] reported similar ﬁndings. In vitro experiments with a
prion protein peptide carrying the A117V mutation
decreased the rate of microtubule formation more efﬁ-
ciently than wild-type PrP106–126. This was thought to be
related to the displacement of tau, where A117V mutation is
more efﬁcient at inhibiting microtubule formation [13].
OPRI mutations, such as 96 bp [21], or 144 bp inserts
[22] into the N-terminal octarepeat region, are character-
ised by a unique pattern of immunoreactivity for PrP,
which is oriented perpendicularly to the cerebellar surface
(Fig. 4k, l), also show a marked tau phosphorylation, which
co-localises with PrP deposits. A case report of a 216 bp
OPRI mutation instead showed a pattern different from
those with a shorter insert, with the formation of large
amyloid plaques, again co-localising with hyperphospho-
rylated tau [27].
Finally, the stop mutation 145X [33] with formation of
plaques and cerebral amyloid angiopathy (‘‘PrP-CAA’’)
showed similar results with tau co-localising to plaques.
The PrP-tau connection (II): tau phosphorylation
in sporadic and variant CJD
Following the observation of hyperphosphorylated tau in
inherited prion diseases with remarkable tropism to amy-
loid plaques, but not in sCJD, several studies analysed this
phenomenon further: Giaccone et al. [36] compared tau
phosphorylation patterns of AD and vCJD and found the
same three bands of 68, 64 and 60 kDa in an immunoblot
probed for tau. Morphologically, hyperphosphorylated tau
co-localised with ﬂorid plaques. However, it was also
found that unlike in AD, there was no detectable soluble
hyperphosphorylated tau in vCJD. In contrast to the ﬁnd-
ings that we report in our series (see below), their study did
not detect hyperphosphorylated tau in brains of sCJD
patients [36]. A study comparing the ultrastructure of prion
amyloid in GSS and vCJD [87] came to a similar conclu-
sion, but in addition found that dystrophic neurites
containing hyperphosphorylated tau occurs in sCJD with
small plaques. It was concluded that plaque-forming prion
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123diseases are capable of generating phospho-tau deposits,
but forms with synaptic PrP deposits may be incapable to
do so [87].
To examine this further, we examined 79 brains from
patients with sporadic CJD and compared them to 12 cases
with inherited prion disease and 5 vCJD cases. We can
Fig. 4 Prion protein-triggered tau phosphorylation in the cerebellum:
upper row deposition of abnormal PrP; sporadic CJD with synaptic
PrP deposition (a–c) or with small plaques (d). e vCJD with heavy
PrP burden with diffuse deposits as well as plaques. The correspond-
ing tau phosphorylation is shown below (f–j): it is approximately
proportional to the PrP
Sc burden and is also closely associated with
plaques. However, an exceptionally strong tau deposit is consistently
seen in vCJD cerebella (i). Inherited forms of prion disease show
variable amounts of p-tau deposits, which do not correlate with the
PrP burden and also do not correlate with the pattern (plaque or
synaptic): The pattern of abnormal PrP deposition is distinct for each
mutation. 96 and 144 bp OPRI form a characteristic striping pattern
perpendicularly to the cerebellar surface (k, l) with moderate tau
labelling in the 96 bp OPRI and very little tau in the 144 bp OPRI.
The extent of tau phosphorylation appears to be independent of the
plaque load, with P102L and A117L cases showing similar tau burden
as in the E200K which features synaptic PrP deposition. Scale bar
120 lm( a–e, n, o); 250 lm( k, l, m) and 40 lm( f–j, p–t)
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123demonstrate for the ﬁrst time that there is indeed presence
of hyperphosphorylated tau in sCJD with synaptic
(Figs. 1j–l, 6i, j) or pericellular PrP, notably also in the
absence of plaques (Figs. 3a–c, 6a, b, e, f). When consid-
ering with the previous reports, we detected a very
substantial formation of phospho-tau positive rods in ﬁve
cases of vCJD, including two cases of blood transfusion
related transmission (Fig. 4j). In those cases with con-
comitant Ab amyloid pathology (mild, n = 14), we found
both patterns, namely granular, rod-shaped PrP-induced tau
inclusions (Fig. 3a–c) and thread-shaped Ab related for-
mations (Fig. 3d–f). Cases of inherited prion disease
(P102L, A117V, D178N, E200K, 96 and 144 bp octarepeat
insert) show accumulation of tau directly associated with
prion protein plaques (Figs. 4p–t, 5f–j).
The PrP-tau connection (III): neocortical PrP
Sc
and pTau correlate in sporadic and in inherited
forms of prion diseases
In our series of sporadic, inherited and variant forms of
prion diseases (n = 79), we found a correlation of prion
protein burden (Fig. 1) and the formation of rod or stub-
shaped tau deposits in the neocortex (Fig. 3; Tables 2, 3).
Previously, the ability of prion protein to hyperphospho-
rylate tau was thought to be associated with the presence of
amyloid plaques, as seen in vCJD, GSS or certain forms of
sCJD. We show here in a large cohort, that indeed synaptic
PrP is directly associated with the presence of minute
deposits of hyperphosphorylated tau. Regions in which
prion protein deposits across the entire thickness of the
cortex also show the presence of tau rods in the same area
(Fig. 6i, m). Other cases where the burden of abnormal
prion protein is restricted to deeper cortical layers show a
distribution of tau rods congruent with prion protein
accumulation and neurodegeneration (Fig. 6a, e). In sCJD,
deposition of tau signiﬁcantly correlates with the intensity
of prion protein load (correlation coefﬁcient r = 0.69,
p\0.01), but does not correlate with disease duration
(r =- 0.037, n.s.). Importantly, the size of tau granules in
sCJD with homogenous synaptic PrP was smaller than that
in sCJD with formation of large PrP granules.
To exclude that the tau phosphorylation was induced by
coexisting Ab amyloid, we stratiﬁed for presence or
absence of Ab amyloid (Tables 2, 3). Almost half of the
cases (n = 36) were entirely free of any form of Ab,a
small number showed patchy, mild and diffuse deposits of
Ab (corresponding to Fig. 2a) (n = 13) and the remainder
showed more intense diffuse Ab and/or core plaques (see
Fig. 2b–e) (n = 27). The morphology of hyperphospho-
rylated tau associated with abnormal prion protein is
remarkably distinct from that elicited by Ab, in particular
in cases of synaptic PrP deposition (Fig. 3). Prion protein
related tau hyperphosphorylation shows as short stub- or
rod-like structures (Fig. 3a–c). The most subtle deposition
forms small rod- or stub-like punctate inclusions (gran-
ules). Their shape resembles granules seen in argyrophilic
grain disease [31]. They do not extend to ﬁbrillary or
‘‘neuritic’’ tau, whilst the most subtle deposition of Ab-
associated tau ﬁbrils occurs in the form of thin, single
neuritic threads in the cortex (Fig. 3d). The next stage of
Ab-induced tau phosphorylation is a more frequent pres-
ence of ﬁbrils (Fig. 3e), and ﬁnally the Ab-induced tau
pathology amounts to a delicate network of dystrophic
processes (Fig. 3f), including neuroﬁbrillary tangles.
Amyloid plaques are generally surrounded by a small
corona of dystrophic neurites, which are well known and
have been frequently described in the literature. The tem-
poral and entorhinal cortex was excluded from the analysis
because this area shows a tau pathology that emerges
independently from Ab or prion protein pathology, and is
likely to represent an independent pathogenic process,
which may explain the ﬁndings of Ishizawa et al. [52]. It is
possible, but difﬁcult to prove whether phosphorylation of
tau in this area may be enhanced by the deposition of prion
protein.
Those forms of prion diseases, which show labelling of
perineuronal networks and small plaques [87], show tau
rods in the vicinity of the perineuronal nets and around
small plaques. In our series, microplaques in sCJD
(Fig. 4d) as well as inherited forms with prominent plaques
(Fig. 5) showed an obvious accumulation of tau at a higher
density (Fig. 6e–h) forming short processes resembling
dystrophic neurites. However, these intraplaque and pe-
riplaque neurites were still more granular than those
associated with Ab plaques. Importantly, this phenomenon
was observed in the absence of any Ab pathology. The
most straightforward explanation of PrP-associated tau
phosphorylation is a simple dose-dependent direct toxicity
whereby PrP amyloid is directly involved in the process.
Alternatively, a critical level of toxic species may be pro-
duced during the conversion process, which is thought to
involve a number of conformational intermediates or side
products during prion conversion and propagation, variably
named as PrP* [1] or PrP
L (lethal) [24]. These toxic (by-)
products, may directly or indirectly trigger pathways
mentioned above and hence contribute to tau phosphory-
lation. However, considering the kinetics of abnormal
protein accumulation in prion diseases [24], and the rela-
tive abundance of prion amyloid in comparison to
hyperphosphorylated tau, makes the latter a likely side
effect rather than a main trigger of prion neuropathogene-
sis. However, the dissection of the events involved in tau
phosphorylation may well be the key to understand prion
neurotoxicity.
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an underestimated feature?
In our series of sporadic, inherited and variant forms of
prion diseases, we detected formation of rod-shaped tau
deposits in the molecular and granular layers. Some forms
of sporadic prion diseases form abundant small plaques,
alongside with synaptic PrP, which is associated with
marked periplaque hyperphosphorylation of tau. The same
observation is made in inherited prion disease with the
predominant formation of cerebellar plaques, such as
P102L GSS, where tau is associated with, but not limited
to, plaques. We show here that sporadic forms trigger tau
phosphorylation in the cerebellum in a ‘‘load-dependent’’
Table 2 Summary of all cases
analysed in this study
All PrP, tau and Ab scores were
obtained using the scoring
scheme shown in Figs. 1, 2,
and 3. In case of multiple
concurrent PrP patterns, the
highest individual score (e.g.
granular score 2 and synaptic
score 1 = ﬁnal score 2) was
used. No cases with cerebellar
Ab were included in this study.
A score 4 for frontal cortex tau
was given in cases that clearly
exceeded the intensity shown in
Fig. 3. One case (sCJD VV)
scored 0 for tau and was
omitted. All other cases had a
tau score of 1 or greater. Cases
with a tau score of 4 (exceeding
the density shown in Fig. 3) are
also shown sCJD MM, MV,
VV sporadic CJD with PRNP
codon 129 genotype,
IPD inherited prion disease
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123fashion (Fig. 4; Table 3), where cases with a relatively low
cerebellar burden of abnormal PrP show fewer rod-shaped
tau positive inclusions (Fig. 4a, f) than those with an
intermediate (Fig. 4b, g) or high PrP load (Fig. 4c, h). This
correlation is statistically signiﬁcant for sCJD (correlation
coefﬁcient r = 0.39, p\0.01) which increases when all
forms of prion diseases are included (r = 0.50 p\0.01).
Tau phosphorylation in the cerebellum occurs in the
molecular layer (Fig. 4f), granular layer (Fig. 4g) and in
the Bergmann glia/Purkinje cell layer (Fig. 4h, i). vCJD is
characterised by a particularly heavy deposition of abnor-
mal PrP in the neocortex and the cerebellum (Fig. 4e),
again there is a signiﬁcant and dense deposition of hyper-
phosphorylated tau in all areas (Fig. 4j, molecular layer).
Fig. 5 PrP-induced tau phosphorylation in cortex of inherited prion
diseases: upper row deposition of abnormal PrP in the frontal cortex;
there is considerable variability of the intensity of PrP
Sc burden and
some forms are characterised by distinct patterns of plaque formation,
as described before. The lower row shows tau deposits corresponding
to the area depicted above. A, 96 bp OPRI mutation with almost
undetectable PrP
Sc load, resulting in tau phosphorylation similar to
the 144 bp OPRI (f, g), despite its signiﬁcantly higher PrP
Sc load (b).
c This case with a P102L mutation shows predominantly diffuse
deposits and only very few plaques, as compared to the very heavily
plaque-forming A117V case (d), both showing similar tau hyper-
phosphorylation (h, i). Another case with no plaque formation,
E200K (e), shows a tau load similar to all other cases (j). Scale bar
a–e 240 lm, f–j 60 lm
Table 3 Statistical analysis of relationship between prion protein deposition, tau phosphorylation and disease duration
Parameter 1 Parameter 2 Number of cases R Signiﬁcance level
Tau (frontal cortex), no Ab amyloid PrP deposits: the strongest score
was taken into account
28 0.69 \0.01
Tau (frontal cortex), no Ab amyloid Duration of illness 28 -0.037 n.s.
Tau (cerebellum), all prion diseases) PrP deposits 69 0.50 \0.01
Tau (cerebellum), all prion diseases Duration of illness 63 0.063 n.s.
Tau (cerebellum), sCJD only PrP deposits 52 0.39 \0.01
Tau (cerebellum), sCJD only Duration of illness 49 -0.16 n.s.
Parameters 1 and 2 were correlated in Pearson’s test (n.s. not signiﬁcant)
Fig. 6 PrP deposits are congruent with hyperphosphorylated tau rods.
Leftcolumn(heatmaps)(a,e);i,mnumbersoftaurodsorgranuleswere
determined per high power ﬁeld on a section in the cortex and a small
strip of adjacent subcortical white matter (immunostaining for AT8
Tau). Each ﬁeld shows the count and a colour coded representation,
(heat map).Middle column b, f, j,n a parallel tissue section, stained for
abnormal PrP shows deposits corresponding to the tau heat map. Right
column c, d, g, h, k, l, o, p high power magniﬁcation of the areas
indicatedbyabluesquareintheheatmapandintheoverviewofthePrP
labelled section (corresponding to ca 25% of the blue square). Arrows
in the tau labelled section indicate very small granules (d, l):
c perineuronal net pattern of abnormal PrP, no plaque formation and
moderate density of tau particles (d), g more intense PrP deposition
and formation of small plaques, which elicit heavier tau deposition (h).
The homogenous synaptic deposit (j) corresponds to a homogenous
distribution oftau, which appears invery small granules (i). Thecoarse
granularPrPdeposits(n,o)areassociatedwithlarger,betterdiscernible
tau granule (p). Scale bar b, f, i 1,500 lm, c, d, g, h, k, l 140 lm
c
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123When comparing the cerebellar tau in brains with
96 bp OPRI, 144 bp OPRI, P102L, A117V and E200K
mutations (Fig. 4k–t), we found that (1) plaque and
synaptic PrP elicit a similar degree of tau hyperphosph-
orylation, but (2) varies between genotypes, which is
particularly evident when comparing with 96 and 144 bp
OPRI (Fig. 4s, t).
These ﬁndings can be interpreted as follows: (1) within
one type of PrP (e.g. sCJD prion protein) the degree of tau
phosphorylation is likely to be dose (or load-) dependent,
Acta Neuropathol (2011) 121:5–20 15
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mutation is able to elicit a response that is speciﬁc to a
given mutation, suggesting that the PrP load and tau
phosphorylation may not be comparable between different
mutations (Fig. 4p–t). The relatively small number of
inherited forms investigated here does not allow for robust
statistical analysis. It has been argued that the long duration
may contribute to the extent of tau phosphorylation, as
vCJD and GSS show signiﬁcantly higher tau load and have
longer incubation times than sCJD. We show here that
there is no correlation between the duration of the illness
and the degree of tau phosphorylation. Prion protein
load appears to be the main factor triggering tau
phosphorylation.
The capacity of cerebellar neurons to hyperphosphory-
late tau has only recently been recognised and is probably
generally underestimated. Primary tauopathies, such as
progressive supranuclear palsy (PSP) are examples of the
capacity of cerebellar Purkinje cells [55, 80] or neurones
of the dentate gyrus [93] to hyperphosphorylate tau. In
patients with PSP or corticobasal degeneration, the clinical
phenotype of cerebellar ataxia is directly associated with
the progressive accumulation of hyperphosphorylated tau
in Purkinje cells [55]. Another disease featuring tau phos-
phorylation in cerebellar neurones is Niemann–Pick
disease where defects in the intracellular trafﬁcking of
exogenous cholesterol causes neurodegeneration. Neuroﬁ-
brillary tangles in the cortex of Niemann–Pick brains are
morphologically similar to those in AD. In the cerebellum,
there is a marked deposition of phospho-tau in the dentate
nucleus and granular layers of the cerebellum [66], but a
remarkable absence of neuroﬁbrillary tangles (NFT) is
noted [17]. Several mouse models have addressed this [18]
and whilst accumulation of hyperphosphorylated tau in
cerebellar granule or Purkinje neurones can be successfully
achieved in several mouse models (stress-induced [76],
Niemann–Pick disease type C [18], pAkt-mediated tau
phosphorylation [71]), no model has yet achieved forma-
tion of NFT, highlighting a speciﬁc pathway or cellular
machinery required for NFT formation that is absent in the
cerebellum [18]. A transgenic mouse expressing human
P301L mutant tau did not show cerebellar tau at all [63].
One of the reasons that cerebellar tau phosphorylation is
widely underestimated is the presence of abundant cortical
phospho-tau in the neocortex in Alzheimer’s disease whilst
it is strikingly absent from the cerebellum, due to the lack
of signiﬁcant Ab accumulation in the cerebellum. If at all,
Ab deposits in the cerebellum only at late stages of the
disease process. Only few studies have demonstrated Ab
deposition in the cerebellum [4] forming diffuse deposits,
but no plaques with dystrophic neurites [58]. Cases of
familial AD can show a signiﬁcant Ab burden in the cer-
ebellum, and can form deposits of various shapes and sizes
[32]. In the same series, cases with sporadic AD showed
diffuse and granular deposits, and may, therefore, have
represented a group with high overall Ab load [4]. More
commonly, vascular Ab may cause cerebellar haemor-
rhages [26] or infarctions [19]. Familial AD cerebella
accumulate mutant Ab42 [54, 72], whilst in sporadic AD,
these deposits are composed of Ab40 amyloid in humans
[70] as well as in experimental models [48].
Most studies including recent multicenter studies of the
neuropathology of AD have not systematically examined
tau hyperphosphorylation in the cerebellum [2, 3]. A recent
biochemical and confocal imaging study has demonstrated
co-localisation of tau and Ab in synaptosomes of all brain
regions, including the cerebellar samples, which showed
the lowest levels within the CNS [30].
In contrast to Alzheimer’s disease where cerebellar Ab
is essentially absent, most sporadic, inherited and trans-
mitted forms (iatrogenic CJD, variant CJD and Kuru) of
prion disease are characterised by a substantial prion pro-
tein deposition in the cerebellum (Fig. 4e). In sCJD,
cerebellar prion protein is often seen as synaptic, homog-
enous deposit in the molecular layer and to a lesser extent,
in the granular layer (Fig. 4a–d). Other typical patterns are
characterised by small granular deposits, which may
become conﬂuent to form microplaques. Kuru, an acquired
prion disease in humans, transmitted by oral uptake during
mortuary feasts in the Fore linguistic group in Papua New
Guinea, is clinically characterised by cerebellar ataxia,
rather than dementia, and shows a marked involvement of
the cerebellum, with formation of dense plaques of variable
sizes [12, 43].
Iatrogenic prion disease can be caused by a wide variety
of procedures, mostly due to the transmission of CJD pri-
ons contained in contaminated growth hormone derived
from human cadavers, or by implantation of contaminated
dura mater grafts [15, 39], transmission of CJD prions
during corneal transplantation [28, 47], contaminated
electroencephalographic (EEG) electrode implantation or
surgical operations using contaminated instruments or
apparatus [14]. The pattern of prion protein deposition is
characterised by synaptic PrP and formation of small and
medium sized plaques in neocortex and in the cerebellum.
Finally, vCJD in the UK and other countries, caused by
human exposure to BSE prions from cattle (Collinge et al.
1996; Bruce et al. 1997; Hill et al. 1997; Collinge 1999;
Asante et al. 2002), is characterised by extensive plaque
formation including the cerebellum.
Conclusion
The capacity of disease-associated PrP to trigger phos-
phorylation of tau has been discovered sequentially. Early
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123reports have described this phenomenon in obvious cases,
where abundant plaques were present. Increasing awareness
and understanding of this phenomenon and reﬁnement of
immunohistochemical and biochemical techniques have
subsequently triggered additional studies, extending the
observation to variant CJD and plaque-forming sporadic
prion diseases. In parallel, the recognition of prionopathies
and prion-like mechanisms as a concept for neurodegener-
ative disease pathogenesis has triggered a wealth of
comparative experiments which led to the discovery of
similarities and functional relationships between Ab and
prion protein. Tau takes part in this process and we have
highlighted the evidence that may represent a mechanism of
amyloid toxicity. Although the relationship between
amyloid toxicity and tau phosphorylation appears straight-
forward in our cohort of sCJD cases, the issue may be more
complicated in inherited prion diseases. Other parameters
that were not systematically addressed in our study are
genetic (tau haplotype, PRNP codon 129 genotype) or
demographic factors (e.g. age of onset). Our data presented
here underpin the concept of amyloid-triggered tau phos-
phorylation, further contribute to the understanding of the
relationship between prion amyloid and tau toxicity and set
the scene for future research on larger cohorts. Furthering
the study of pathways involved in tau phosphorylation may
also be the key to understand prion neurotoxicity.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
References
1. Aguzzi A, Weissmann C (1997) Prion research: the next frontiers.
Nature 389:795–798
2. Alafuzoff I, Arzberger T, Al-Sarraj S, Bodi I, Bogdanovic N,
Braak H, Bugiani O, Del-Tredici K, Ferrer I, Gelpi E, Giaccone
G, Graeber MB, Ince P, Kamphorst W, King A, Korkolopoulou
P, Kovacs GG, Larionov S, Meyronet D, Monoranu C, Parchi P,
Patsouris E, Roggendorf W, Seilhean D, Tagliavini F, Stadel-
mann C, Streichenberger N, Thal DR, Wharton SB, Kretzschmar
H (2008) Staging of neuroﬁbrillary pathology in Alzheimer’s
disease: a study of the BrainNet Europe Consortium. Brain Pathol
18:484–496
3. Alafuzoff I, Pikkarainen M, Al-Sarraj S, Arzberger T, Bell J,
Bodi I, Bogdanovic N, Budka H, Bugiani O, Ferrer I, Gelpi E,
Giaccone G, Graeber MB, Hauw JJ, Kamphorst W, King A, Kopp
N, Korkolopoulou P, Kovacs GG, Meyronet D, Parchi P, Pat-
souris E, Preusser M, Ravid R, Roggendorf W, Seilhean D,
Streichenberger N, Thal DR, Kretzschmar H (2006) Interlabora-
tory comparison of assessments of Alzheimer disease-related
lesions: a study of the BrainNet Europe Consortium. J Neuro-
pathol Exp Neurol 65:740–757
4. Alafuzoff I, Thal DR, Arzberger T, Bogdanovic N, Al-Sarraj S,
Bodi I, Boluda S, Bugiani O, Duyckaerts C, Gelpi E, Gentleman
S, Giaccone G, Graeber M, Hortobagyi T, Hoftberger R, Ince P,
Ironside JW, Kavantzas N, King A, Korkolopoulou P, Kovacs
GG, Meyronet D, Monoranu C, Nilsson T, Parchi P, Patsouris E,
Pikkarainen M, Revesz T, Rozemuller A, Seilhean D, Schulz-
Schaeffer W, Streichenberger N, Wharton SB, Kretzschmar H
(2009) Assessment of beta-amyloid deposits in human brain: a
study of the BrainNet Europe Consortium. Acta Neuropathol
117:309–320
5. Amano N, Yagishita S, Yokoi S, Itoh Y, Kinoshita J, Mizutani T,
Matsuishi T (1992) Gerstmann–Straussler syndrome–a variant
type: amyloid plaques and Alzheimer’s neuroﬁbrillary tangles in
cerebral cortex. Acta Neuropathol Berl 84:15–23
6. Asante EA, Linehan JM, Desbruslais M, Joiner S, Gowland I,
Wood AL, Welch J, Hill AF, Lloyd SE, Wadsworth JD, Collinge
J (2002) BSE prions propagate as either variant CJD-like or
sporadic CJD-like prion strains in transgenic mice expressing
human prion protein. EMBO J 21:6358–6366
7. Bitan G, Fradinger EA, Spring SM, Teplow DB (2005) Neuro-
toxic protein oligomers–what you see is not always what you get.
Amyloid 12:88–95
8. Boellaard JW, Doerr Schott J, Schlote W (1993) Miniplaques and
shapeless cerebral amyloid deposits in a case of Gerstmann–
Straussler–Scheinker’s syndrome. Acta Neuropathol Berl 86:
532–535
9. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC,
Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M
(2007) Induction of tau pathology by intracerebral infusion of
amyloid-beta-containing brain extract and by amyloid-beta
deposition in APP 9 Tau transgenic mice. Am J Pathol 171:
2012–2020
10. Braak H, Braak E (1995) Staging of Alzheimer’s disease-related
neuroﬁbrillary changes. Neurobiol Aging 16:271–278 (discussion
278–284)
11. Braak H, Braak E, Bohl J (1993) Staging of Alzheimer-related
cortical destruction. Eur Neurol 33:403–408
12. Brandner S, Whitﬁeld J, Boone K, Puwa A, O’Malley C, Linehan
JM, Joiner S, Scaravilli F, Calder I, PA M, Wadsworth JD,
Collinge J (2008) Central and peripheral pathology of kuru:
pathological analysis of a recent case and comparison with other
forms of human prion disease. Philos Trans R Soc Lond B Biol
Sci 363:3755–3763
13. Brown DR (2000) Altered toxicity of the prion protein peptide
PrP106–126 carrying the Ala(117)[Val mutation. Biochem J
346(Pt 3):785–791
14. Brown P, Preece M, Brandel JP, Sato T, McShane L, Zerr I,
Fletcher A, Will RG, Pocchiari M, Cashman NR, d’Aignaux JH,
Cervenakova L, Fradkin J, Schonberger LB, Collins SJ (2000)
Iatrogenic Creutzfeldt–Jakob disease at the millennium. Neurol-
ogy 55:1075–1081
15. Brown P, Preece MA, Will RG (1992) ‘‘Friendly ﬁre’’ in medi-
cine: hormones, homografts, and Creutzfeldt–Jakob disease.
Lancet 340:24–27
16. Bruce ME, Will RG, Ironside JW, McConnell I, Drummond D,
Suttie A, McCardle L, Chree A, Hope J, Birkett C, Cousens S,
Fraser H, Bostock CJ (1997) Transmissions to mice indicate that
‘new variant’ CJD is caused by the BSE agent. Nature 389:498–
501
17. Bu B, Klunemann H, Suzuki K, Li J, Bird T, Jin LW, Vincent I
(2002) Niemann–Pick disease type C yields possible clue for why
cerebellar neurons do not form neuroﬁbrillary tangles. Neurobiol
Dis 11:285–297
18. Bu B, Li J, Davies P, Vincent I (2002) Deregulation of cdk5,
hyperphosphorylation, and cytoskeletal pathology in the Nie-
mann–Pick type C murine model. J Neurosci 22:6515–6525
19. Cadavid D, Mena H, Koeller K, Frommelt RA (2000) Cerebral
beta amyloid angiopathy is a risk factor for cerebral ischemic
Acta Neuropathol (2011) 121:5–20 17
123infarction: a case control study in human brain biopsies. J Neu-
ropathol Exp Neurol 59:768–773
20. Camins A, Verdaguer E, Folch J, Canudas AM, Pallas M (2006)
The role of CDK5/P25 formation/inhibition in neurodegenera-
tion. Drug News Perspect 19:453–460
21. Campbell TA, Palmer MS, Will RG, Gibb WR, Luthert PJ, Col-
linge J(1996) A prion disease with a novel 96-base pair insertional
mutation in the prion protein gene. Neurology 46:761–766
22. Capellari S, Vital C, Parchi P, Petersen RB, Ferrer X, Jarnier D,
Pegoraro E, Gambetti P, Julien J (1997) Familial prion disease
with a novel 144-bp insertion in the prion protein gene in a
Basque family. Neurology 49:133–141
23. Clavaguera F, Bolmont T, Crowther RA, Abramowski D, Frank
S, Probst A, Fraser G, Stalder AK, Beibel M, Staufenbiel M,
Jucker M, Goedert M, Tolnay M (2009) Transmission and
spreading of tauopathy in transgenic mouse brain. Nat Cell Biol
11:909–913
24. Collinge J, Clarke AR (2007) A general model of prion strains
and their pathogenicity. Science 318:930–936
25. Collinge J, Sidle KC, Meads J, Ironside J, Hill AF (1996)
Molecular analysis of prion strain variation and the aetiology of
‘new variant’ CJD. Nature 383:685–690
26. Cuny E, Loiseau H, Rivel J, Vital C, Castel JP (1996) Amyloid
angiopathy-related cerebellar hemorrhage. Surg Neurol 46:
235–239
27. Duchen LW, Poulter M, Harding AE (1993) Dementia associated
with a 216 base pair insertion in the prion protein gene. Clinical
and neuropathological features. Brain 116:555–567
28. Duffy P, Wolf J, Collins G, DeVoe AG, Streeten B, Cowen D
(1974) Possible person-to-person transmission of Creutzfeldt–
Jakob disease. N Engl J Med 290:692–693
29. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH,
Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M
(2009) Induction of cerebral beta-amyloidosis: intracerebral
versus systemic Abeta inoculation. Proc Natl Acad Sci USA
106:12926–12931
30. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM,
Gylys KH (2008) Co-localization of amyloid beta and tau
pathology in Alzheimer’s disease synaptosomes. Am J Pathol
172:1683–1692
31. Ferrer I, Santpere G, van Leeuwen FW (2008) Argyrophilic grain
disease. Brain 131:1416–1432
32. Fukutani Y, Cairns NJ, Rossor MN, Lantos PL (1997) Cerebellar
pathology in sporadic and familial Alzheimer’s disease including
APP 717 (Val[Ile) mutation cases: a morphometric investiga-
tion. J Neurol Sci 149:177–184
33. Ghetti B, Piccardo P, Spillantini MG, Ichimiya Y, Porro M,
Perini F, Kitamoto T, Tateishi J, Seiler C, Frangione B,
Bugiani O, Giaccone G, Prelli F, Goedert M, Dlouhy SR,
Tagliavini F (1996) Vascular variant of prion protein cerebral
amyloidosis with tau-positive neuroﬁbrillary tangles: the phe-
notype of the stop codon 145 mutation in PRNP. Proc Natl
Acad Sci USA 93:744–748
34. Ghetti B, Tagliavini F, Giaccone G, Bugiani O, Frangione B,
Farlow MR, Dlouhy SR (1994) Familial Gerstmann–Straussler–
Scheinker disease with neuroﬁbrillary tangles. Mol Neurobiol
8:41–48
35. Ghetti B, Tagliavini F, Masters CL, Beyreuther K, Giaccone G,
Verga L, Farlow MR, Conneally PM, Dlouhy SR, Azzarelli B
et al (1989) Gerstmann–Straussler–Scheinker disease, II: Neu-
roﬁbrillary tangles and plaques with PrP-amyloid coexist in an
affected family. Neurology 39:1453–1461
36. Giaccone G, Mangieri M, Capobianco R, Limido L, Hauw JJ,
Haik S, Fociani P, Bugiani O, Tagliavini F (2008) Tauopathy in
human and experimental variant Creutzfeldt–Jakob disease.
Neurobiol Aging 29:1864–1873
37. Glabe C (2001) Intracellular mechanisms of amyloid accumula-
tion and pathogenesis in Alzheimer’s disease. J Mol Neurosci
17:137–145
38. Gotz J, Chen F, van Dorpe J, Nitsch RM (2001) Formation of
neuroﬁbrillary tangles in P301l tau transgenic mice induced by
Abeta 42 ﬁbrils. Science 293:1491–1495
39. Grifﬁn JP (1991) Transmission of Creutzfeldt–Jakob disease by
investigative and therapeutic procedures. Adverse Drug React
Toxicol Rev 10:89–98
40. Grifﬁth JS (1967) Self-replication and scrapie. Nature 215:1043–
1044
41. Gunther EC, Strittmatter SM (2010) beta-Amyloid oligomers and
cellular prion protein in Alzheimer’s disease. J Mol Med 88:331–
338
42. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neuro-
degeneration: lessons from the Alzheimer’s amyloid beta-
peptide. Nat Rev Mol Cell Biol 8:101–112
43. Hainfellner JA, Parchi P, Kitamoto T, Jarius C, Gambetti P,
Budka H (1999) A novel phenotype in familial Creutzfeldt–Jakob
disease: prion protein gene E200K mutation coupled with valine
at codon 129 and type 2 protease-resistant prion protein. Ann
Neurol 45:812–816
44. Hardy JA, Higgins GA (1992) Alzheimer’s disease: the amyloid
cascade hypothesis. Science 256:184–185
45. Hernandez F, de Barreda EG, Fuster-Matanzo A, Goni-Oliver P,
Lucas JJ, Avila J (2009) The role of GSK3 in Alzheimer disease.
Brain Res Bull 80:248–250
46. Hernandez F, Gomez de Barreda E, Fuster-Matanzo A, Lucas JJ,
Avila J (2009) GSK3: a possible link between beta amyloid
peptide and tau protein. Exp Neurol. doi:10.1016/j.physletb.
2003.10.071
47. Herzberg L (1979) Creutzfeld–Jakob disease and corneal grafts.
Med J Aust 1:248
48. Herzig MC, Winkler DT, Burgermeister P, Pfeifer M, Kohler E,
Schmidt SD, Danner S, Abramowski D, Sturchler-Pierrat C,
Burki K, van Duinen SG, Maat-Schieman ML, Staufenbiel M,
Mathews PM, Jucker M (2004) Abeta is targeted to the vascu-
lature in a mouse model of hereditary cerebral hemorrhage with
amyloidosis. Nat Neurosci 7:954–960
49. Hill AF, Desbruslais M, Joiner S, Sidle KC, Gowland I, Collinge
J, Doey LJ, Lantos P (1997) The same prion strain causes vCJD
and BSE. Nature 389:448–450, 526
50. Holton JL, Ghiso J, Lashley T, Rostagno A, Guerin CJ, Gibb G,
Houlden H, Ayling H, Martinian L, Anderton BH, Wood NW,
Vidal R, Plant G, Frangione B, Revesz T (2001) Regional dis-
tribution of amyloid-Bri deposition and its association with
neuroﬁbrillary degeneration in familial British dementia. Am J
Pathol 158:515–526
51. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis
of Alzheimer’s disease. J Neurochem 104:1433–1439
52. Ishizawa K, Komori T, Shimazu T, Yamamoto T, Kitamoto T,
Shimazu K, Hirose T (2002) Hyperphosphorylated tau deposition
parallels prion protein burden in a case of Gerstmann–Straussler–
Scheinker syndrome P102L mutation complicated with dementia.
Acta Neuropathol 104:342–350
53. Itoh Y, Yamada M, Hayakawa M, Shozawa T, Tanaka J,
Matsushita M, Kitamoto T, Tateishi J, Otomo E (1994) A
variant of Gerstmann–Straussler–Scheinker disease carrying
codon 105 mutation with codon 129 polymorphism of the
prion protein gene: a clinicopathological study. J Neurol Sci
127:77–86
54. Kalaria RN, Cohen DL, Greenberg BD, Savage MJ, Bogdanovic
NE, Winblad B, Lannfelt L, Adem A (1996) Abundance of the
longer A beta 42 in neocortical and cerebrovascular amyloid beta
deposits in Swedish familial Alzheimer’s disease and Down’s
syndrome. Neuroreport 7:1377–1381
18 Acta Neuropathol (2011) 121:5–20
12355. Kanazawa M, Shimohata T, Toyoshima Y, Tada M, Kakita A,
Morita T, Ozawa T, Takahashi H, Nishizawa M (2009) Cere-
bellar involvement in progressive supranuclear palsy: a clinico-
pathological study. Mov Disord 24:1312–1318
56. Kerr F, Rickle A, Nayeem N, Brandner S, Cowburn RF, Love-
stone S (2006) PTEN, a negative regulator of PI3 kinase
signalling, alters tau phosphorylation in cells by mechanisms
independent of GSK-3. FEBS Lett 580:3121–3128
57. Krasnianski A, von Ahsen N, Heinemann U, Meissner B,
Kretzschmar HA, Armstrong VW, Zerr I (2008) ApoE distribu-
tion and family history in genetic prion diseases in Germany.
J Mol Neurosci 34:45–50
58. Larner AJ (1997) The cerebellum in Alzheimer’s disease.
Dement Geriatr Cogn Disord 8:203–209
59. Lauren J, Gimbel DA, Nygaard HB, Gilbert JW, Strittmatter SM
(2009) Cellular prion protein mediates impairment of synaptic
plasticity by amyloid-beta oligomers. Nature 457:1128–1132
60. Lebel M, Patenaude C, Allyson J, Massicotte G, Cyr M (2009)
Dopamine D1 receptor activation induces tau phosphorylation via
cdk5 and GSK3 signaling pathways. Neuropharmacology 57:
392–402
61. Lesne S, Koh MT, Kotilinek L, Kayed R, Glabe CG, Yang A,
Gallagher M, Ashe KH (2006) A speciﬁc amyloid-beta protein
assembly in the brain impairs memory. Nature 440:352–357
62. Lewis J, Dickson DW, Lin WL, Chisholm L, Corral A, Jones G,
Yen SH, Sahara N, Skipper L, Yager D, Eckman C, Hardy J,
Hutton M, McGowan E (2001) Enhanced neuroﬁbrillary degen-
eration in transgenic mice expressing mutant tau and APP.
Science 293:1487–1491
63. Lewis J, McGowan E, Rockwood J, Melrose H, Nacharaju P, Van
Slegtenhorst M, Gwinn-Hardy K, Paul Murphy M, Baker M, Yu
X, Duff K, Hardy J, Corral A, Lin WL, Yen SH, Dickson DW,
Davies P, Hutton M (2000) Neuroﬁbrillary tangles, amyotrophy
and progressive motor disturbance in mice expressing mutant
(P301L) tau protein. Nat Genet 25:402–405
64. Lopes JP, Oliveira CR, Agostinho P (2007) Role of cyclin-
dependent kinase 5 in the neurodegenerative process triggered by
amyloid-Beta and prion peptides: implications for Alzheimer’s
disease and prion-related encephalopathies. Cell Mol Neurobiol
27:943–957
65. Lopes JP, Oliveira CR, Agostinho P (2009) Cdk5 acts as a
mediator of neuronal cell cycle re-entry triggered by amyloid-
beta and prion peptides. Cell Cycle 8:97–104
66. Love S, Bridges LR, Case CP (1995) Neuroﬁbrillary tangles in
Niemann–Pick disease type C. Brain 118(Pt 1):119–129
67. Marino S, Krimpenfort P, Leung C, van der Korput HA, Trapman
J, Camenisch I, Berns A, Brandner S (2002) PTEN is essential for
cell migration but not for fate determination and tumourigenesis
in the cerebellum. Development 129:3513–3522
68. Mead S, James-Galton M, Revesz T, Doshi RB, Harwood G, Pan
EL, Ghiso J, Frangione B, Plant G (2000) Familial British
dementia with amyloid angiopathy: early clinical, neuropsycho-
logical and imaging ﬁndings. Brain 123(Pt 5):975–991
69. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S,
Schaefer C, Kilger E, Neuenschwander A, Abramowski D, Frey
P, Jaton AL, Vigouret JM, Paganetti P, Walsh DM, Mathews PM,
Ghiso J, Staufenbiel M, Walker LC, Jucker M (2006) Exogenous
induction of cerebral beta-amyloidogenesis is governed by agent
and host. Science 313:1781–1784
70. Mori H, Takio K, Ogawara M, Selkoe DJ (1992) Mass spec-
trometry of puriﬁed amyloid beta protein in Alzheimer’s disease.
J Biol Chem 267:17082–17086
71. Nayeem N, Kerr F, Naumann H, Linehan J, Lovestone S,
Brandner S (2007) Hyperphosphorylation of tau and neuroﬁla-
ments and activation of CDK5 and ERK1/2 in PTEN-deﬁcient
cerebella. Mol Cell Neurosci 34:400–408
72. Nishitsuji K, Tomiyama T, Ishibashi K, Kametani F, Ozawa K,
Okada R, Maat-Schieman ML, Roos RA, Iwai K, Mori H (2007)
Cerebral vascular accumulation of Dutch-type Abeta42, but not
wild-type Abeta42, in hereditary cerebral hemorrhage with
amyloidosis, Dutch type. J Neurosci Res 85:2917–2923
73. Nochlin D, Sumi SM, Bird TD, Snow AD, Leventhal CM,
Beyreuther K, Masters CL (1989) Familial dementia with PrP-
positive amyloid plaques: a variant of Gerstmann–Straussler
syndrome. Neurology 39:910–918
74. Nygaard HB, Strittmatter SM (2009) Cellular prion protein
mediates the toxicity of beta-amyloid oligomers: implications for
Alzheimer disease. Arch Neurol 66:1325–1328
75. Oddo S, Billings L, Kesslak JP, Cribbs DH, LaFerla FM (2004)
Abeta immunotherapy leads to clearance of early, but not late,
hyperphosphorylated tau aggregates via the proteasome. Neuron
43:321–332
76. Okawa Y, Ishiguro K, Fujita SC (2003) Stress-induced hyper-
phosphorylationoftauinthemousebrain.FEBSLett535:183–189
77. Parkin ET, Watt NT, Hussain I, Eckman EA, Eckman CB,
Manson JC, Baybutt HN, Turner AJ, Hooper NM (2007) Cellular
prion protein regulates beta-secretase cleavage of the Alzhei-
mer’s amyloid precursor protein. Proc Natl Acad Sci USA
104:11062–11067
78. Patrick GN, Zukerberg L, Nikolic M, de la Monte S, Dikkes P,
Tsai LH (1999) Conversion of p35 to p25 deregulates Cdk5
activity and promotes neurodegeneration. Nature 402:615–622
79. Perez M, Rojo AI, Wandosell F, Diaz-Nido J, Avila J (2003)
Prion peptide induces neuronal cell death through a pathway
involving glycogen synthase kinase 3. Biochem J 372:129–136
80. Piao YS, Hayashi S, Wakabayashi K, Kakita A, Aida I, Yamada
M, Takahashi H (2002) Cerebellar cortical tau pathology in
progressive supranuclear palsy and corticobasal degeneration.
Acta Neuropathol 103:469–474
81. Pimplikar SW (2009) Reassessing the amyloid cascade hypothesis
of Alzheimer’s disease. Int J Biochem Cell Biol 41:1261–1268
82. Plant GT, Revesz T, Barnard RO, Harding AE, Gautier-Smith PC
(1990) Familial cerebral amyloid angiopathy with nonneuritic
amyloid plaque formation. Brain 113(Pt 3):721–747
83. Prusiner SB (1982) Novel proteinaceous infectious particles
cause scrapie. Science 216:136–144
84. Puri R, Suzuki T, Yamakawa K, Ganesh S (2009) Hyperphosph-
orylation and aggregation of Tau in laforin-deﬁcient mice, an
animal model for Lafora disease. J Biol Chem 284:22657–22663
85. Revesz T, Holton JL, Doshi B, Anderton BH, Scaravilli F, Plant
GT (1999) Cytoskeletal pathology in familial cerebral amyloid
angiopathy (British type) with non-neuritic amyloid plaque for-
mation. Acta Neuropathol 97:170–176
86. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Shepardson NE,
Smith I, Brett FM, Farrell MA, Rowan MJ, Lemere CA, Regan
CM, Walsh DM, Sabatini BL, Selkoe DJ (2008) Amyloid-beta
protein dimers isolated directly from Alzheimer’s brains impair
synaptic plasticity and memory. Nat Med 14:837–842
87. Sikorska B, Liberski PP, Sobow T, Budka H, Ironside JW (2009)
Ultrastructural study of ﬂorid plaques in variant Creutzfeldt–
Jakob disease: a comparison with amyloid plaques in kuru,
sporadic Creutzfeldt–Jakob disease and Gerstmann–Straussler–
Scheinker disease. Neuropathol Appl Neurobiol 35:46–59
88. Sobue K, Agarwal-Mawal A, Li W, Sun W, Miura Y, Paudel HK
(2000) Interaction of neuronal Cdc2-like protein kinase with
microtubule-associated protein tau. J Biol Chem 275:16673–
16680
89. Tagliavini F, Prelli F, Ghiso J, Bugiani O, Serban D, Prusiner SB,
Farlow MR, Ghetti B, Frangione B (1991) Amyloid protein of
Gerstmann–Straussler–Scheinker disease (Indiana kindred) is an
11 kD fragment of prion protein with an N-terminal glycine at
codon 58. EMBO J 10:513–519
Acta Neuropathol (2011) 121:5–20 19
12390. Townsend M, Shankar GM, Mehta T, Walsh DM, Selkoe DJ
(2006) Effects of secreted oligomers of amyloid beta-protein
on hippocampal synaptic plasticity: a potent role for trimers.
J Physiol 572:477–492
91. Tranchant C, Doh Ura K, Steinmetz G, Chevalier Y, Kitamoto T,
Tateishi J, Warter JM (1991) Mutation of codon 117 of the prion
gene in Gerstmann–Straussler–Scheinker disease. Rev Neurol
Paris 147:274–278
92. Webb TE, Poulter M, Beck J, Uphill J, Adamson G, Campbell T,
Linehan J, Powell C, Brandner S, Pal S, Siddique D, Wadsworth
JD, Joiner S, Alner K, Petersen C, Hampson S, Rhymes C, Treacy
C, Storey E, Geschwind MD, Nemeth AH, Wroe S, Collinge J,
Mead S (2008) Phenotypic heterogeneity and genetic modiﬁca-
tion of P102L inherited prion disease in an international series.
Brain 131:2632–2646
93. Williams DR, Holton JL, Strand C, Pittman A, de Silva R, Lees
AJ, Revesz T (2007) Pathological tau burden and distribution
distinguishes progressive supranuclear palsy-parkinsonism from
Richardson’s syndrome. Brain 130:1566–1576
94. Worster-Drought C, MW Hill TR (1933) Familial presenile
dementia with spastic paralysis. J Neurol Psychopathol 14:27–34
95. Yamada M, Itoh Y, Inaba A, Wada Y, Takashima M, Satoh S,
Kamata T, Okeda R, Kayano T, Suematsu N, Kitamoto T, Otomo
E, Matsushita M, Mizusawa H (1999) An inherited prion disease
with a PrP P105L mutation: clinicopathologic and PrP hetero-
geneity (in process citation). Neurology 53:181–188
96. Zhang M, Li J, Chakrabarty P, Bu B, Vincent I (2004) Cyclin-
dependent kinase inhibitors attenuate protein hyperphosphoryla-
tion,cytoskeletallesionformation,andmotordefectsinNiemann–
Pick type C mice. Am J Pathol 165:843–853
20 Acta Neuropathol (2011) 121:5–20
123